glp-1 and kidney disease Receptor Agonists Diabetic Disease: A Call of Attention to Nephrologists Glucagon-Like Peptide-1 Receptor Agonist Use

New data reveals that sales growth of semaglutide and GLP-1 therapies slowed...

This case highlights the need for gradual insulin tapering and close monitoring while transitioning from insulin therapy to GIP/GLP-1 receptor agonists.

GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose

The Pentelute Lab aims to invent new chemistry for the efficient and selective modification of proteins, to hijack these biological machines for efficient drug delivery into cells and to create new machines to rapidly and efficiently manufacture peptides and proteins.

OKLAHOMA CITY The success of GLP-1 medications for treating Type 2 diabetes and obesity naturally leads to a related question: Do GLP-1 drugs affect cancer risk, which is often associated with obesity and Type 2 diabetes

P=0.2